The prevalence of infections which have deleterious effects to either the mother or the fetus during pregnancy are unknown in Cameroon. To formulate appropriate antenatal screening policies for the Central Mother and Child Clinic in Yaounde, we tested random sera obtained from 1,014 stored samples previously obtained from pregnant women. One hundred and fifty sera were tested for the presence of the hepatitis B surface antigen (HBsAg), 544 for syphilis antibodies, 192 for antibodies to rubella and 192 for antibodies to Toxoplasma gondii. We found the HBsAg in 25.3% (38/150) of the subjects, antibodies against syphilis in 15.9% (87/544), antibodies to the rubella virus in 83.9% (161/192) and evidence of toxoplasma infection in 77.1% (148/192). Of the 38 HBsAg-positive subjects, 5.2% and 55.3% were positive for the HBe antigen and HBe antibody, respectively. We found a high prevalence for these infections in the antenatal clinical attendants. The data will be used to develop an appropriate control strategy for them.

From June 1994 to July 1996, 4100 pregnant women living in Yaounde, Cameroon, were tested for human immunodeficiency virus type 1 (HIV-1) and syphilis. The HIV seroprevalence was 4.2% (95% confidence interval (CI): 3.6%-4.8%), and that of antibodies to Treponema pallidum was 17.4% (95% CI: 16.3%-18.6%) (HIV infection was twice as common in women with positive syphilis serology) (7.2% vs 3.6%). Over the study period, the antenatal seroprevalence of syphilis remained stable, while there was an increase in the HIV seroprevalence rate. There was an increase in HIV seropositivity in women uninfected with syphilis between 1994/1995 and 1995/1996 from 2.9% to 4.3%. By the end of the study, HIV infection was no commoner in women with negative compared with positive syphilis serology. It is therefore postulated that HIV infection in Yaounde has entered the general, sexually active female population. We suggest that management of pregnant women in Cameroon should include routine screening for both HIV infection and other sexually transmitted diseases (STDs).

No abstract